Clover Corporation Limited · ASX:CLV
Clover — Shareholder Meeting (November 2005)
17 slides from Clover's shareholder meeting presentation, Nov 16, 2005
Slide 1: Clover Corporation Limited AGM cover letter
Cle r R Clover Corporation Limited << ABN 85 003 622 866 4 Floor, 160 Pitt Street SYDNEY. N.S.W. 2000 Telephone + 61 2 9232 7166 Facsimile + 61 2 9233 1025 16 November, 2005. The Manager — Companies, Australian Stock Exchange Limited Exchange Centre, 20 Bridge Street, SYDNEY. N.S.W. 2000 Dear Sir, C
Slide 2: Report to Clover Corporation Ltd, 16 November 2005
REPORT TO CLOVER CORPORATION LTD 16™ NOVEMBER, 2005 Prepared by P.J.Lancaster, CEO Nu-Mega Ingredients Pty Lid Over the last 2 years Nu-Mega has invested resources in working with Prospective customers with innovative new products utilizing our Omega-3 microencapsulated products. We have developed m
Slide 3: Omega-3 DHA and EPA claims and clinical research
Omega-3 DHA and EPA claims are high on their priority list. For the first time the National Health and Medical Research Council will include recommendations for long chain Omega-3 intakes along with revised vitamin and mineral RDIs. This is expected to be released at the end of this year. Clinical r
Slide 4: Alzheimers and continuing Omega-3 research
Alzheimers - Fish consumption has been associated with slower cognitive decline with age®. Animal studies have indicated that Omega-3 DHA reduces indications of Alzheimer-like brain deterioration. It has been suggested that DHA has a much more favourable safety profile compared to other treatments s
Slide 5: Asia and Europe market update and new product launches
opposition. This research project in conjunction with FSA will be ongoing. A number of new products are scheduled for launch by our customers between December 05 and March 06 which will bring in new revenues over $0.5 million per annum. The infant nutrition market in Asia is growing significantly an
Slide 6: References
References 1. McLennan P, personal communication, 2005 2. Mihrshahi S et al. Effect of omega-3 fatty acid concentrations in plasma on symptoms of asthma at 18 months of age. Pediatr Allergy Immunol. 2004 Dec; 15(6):517-22. 3. http:/Awww.unisa edu.au/researcher/issue/2005March/obesity.asp accessed 11
Slide 7: Presentation to Clover Corporation Ltd: Tuna Oil Quality Improvement; Single Cell Omega 3 Oils
PRESENTATION TO CLOVER CORPORATION LTD Tuna Oil Quality Improvement 2. Single Cell Omega 3 Oils CTRVETI
Slide 8: Project Objectives
PROJECT OBJECTIVES tL Improve the tuna oil quality to enable more _ successful incorporation of omega 3 powder into finished products by: ¢ Further reducing the fish taste and odour of the oil and powder * Reducing pesticide levels, eg PCBs and organochlorines such as DDE & DDT * Improving shelf lif
Slide 9: Deodorization Technology
Deodorization Technology m Various deodorization technology is being used overseas in the vegetable and fish oil refining industries m Reviewed two leading technologies in Europe and have selected best elements of both # Refined tuna oil produced at the Nu-Mega refinery in Melbourne was sent to Euro
Slide 10: Deodorisation Results
Deodorisation Results « Excellent Odour and Taste m Good Pesticide Reduction m= Microencapsulation trials have resulted in superior quality powders # Foods formulated with the powder have less fish odour and taste CTRVETI
Slide 11: Strategy
Strategy = Target date for commissioned new deodorisation equipment at Altona factory May 2006 m# Lead time of 7 months for construction, installation and commissioning | i Have secured contract deodorization until new equipment is installed m From December 2005 Nu-Mega powders will be made with low
Slide 12: Single Cell Omega oils
Single Cell Omega 3 oils = The primary natural source of omega 3’s is algae and other marine microorganisms such as thraustochytrids . # Fish, like humans, cannot produce essential fatty acids which are the precursors of omega 3’s and must consume them as part of their diet. = These microorganisms c
Slide 13: Why do we need another source of omega oil?
Why do we need another source of omega 3 oil? w# The market for functional foods containing LCPUFA omega 3’s with high levels of DHA is growing rapidly. As research demonstrates the key human disease areas addressed by DHA the demand for omega 3 oils high in DHA will not be met by current fish oil s
Slide 14: Why do we need another source of omega oil? cont.
Why do we need another source of omega 3 oil? cont. w The micro-organisms selected have high levels of DHA # There are other potential omega 3 and omega 6 fatty acids that could be produced # The micro-organisms produce natural pigments and anti- oxidants ® Project Objectives — Production of a bioma
Slide 15: Clovers Research Partners
Clovers Research Partners = CSIRO Marine and Atmospheric Research — Supply of micro-organisms from marine algal collection — Supply of analytical services and technical support » CRC Bioproducts — Supply of fermentation pilot plant — Supply of technical expertise and staff for scale up work ccino§ M
Slide 16: What are Thraustochytrids?
What are Thraustochytrids? ¢ Unicellular marine eukaryotes ¢ Heterotrophic * Have been previously classed as fungi, slime moulds, protozoa, primitive algae
Slide 17: Project Funding
Project Funding # Clover Corporation 50% # National Food Industry Strategy 50% = Food Innovation Grant $998,850 # Total project spend to 30 June 2007 $1.997 mill assuming project milestones are met. m We acknowledge the support of the Federal Government and their funding of this research with a Food